+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Ischemic Heart Disease (IHD) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4828703
  • Report
  • August 2019
  • Region: Global
  • 105 pages
  • IMARC Group
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Actelion
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • MORE
The global ischemic heart disease (IHD) drugs market is expected to grow at a CAGR of around 3% during 2019-2024. Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

This latest report provides a deep insight into the global ischemic heart disease (IHD) drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the ischemic heart disease (IHD) drugs market in any manner.

Report Coverage:

Historical, Current and Future Market Trends

Market Breakup by Disease Class:
Angina Pectoris
Myocardial Infarction

Market Breakup by Drug Class:
Anti-Dyslipidemic Drugs
Calcium Channel Blockers
ACE Inhibitors
Antithrombotic Agents

Market Breakup by Region:
North America
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AstraZeneca plc, Bayer AG, Eli Lilly, Novartis, Pfizer Inc., Sanofi S.A., Actelion, Baxter International Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Amgen Inc., F.Hoffmann-La Roche, GlaxoSmithKline, Merck, Eisai Co., Ltd., etc.

Key Questions Answered in This Report:

How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
What is the breakup of the market based on the disease class?
What is the breakup of the market based on the drug class?
What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?
Note: Product cover images may vary from those shown
2 of 4


  • Actelion
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Ischemic Heart Disease (IHD) Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Disease Class
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Region
5.6 Market Forecast

6 Market Breakup by Disease Class
6.1 Angina Pectoris
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Myocardial Infarction
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Drug Class
7.1 Anti-Dyslipidemic Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Calcium Channel Blockers
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Beta-Blockers
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 ACE Inhibitors
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 ARBs
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Vasodilators
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Antithrombotic Agents
7.7.1 Market Trends
7.7.2 Market Forecast

8 Market Breakup by Region
8.1 North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Latin America
8.5.1 Market Trends
8.5.2 Market Forecast

9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AstraZeneca plc
13.3.2 Bayer AG
13.3.3 Eli Lilly
13.3.4 Novartis
13.3.5 Pfizer Inc.
13.3.6 Sanofi S.A.
13.3.7 Actelion
13.3.8 Baxter International Inc.
13.3.9 Boehringer Ingelheim
13.3.10 Bristol-Myers Squibb
13.3.11 Amgen Inc.
13.3.12 F.Hoffmann-La Roche
13.3.13 GlaxoSmithKline
13.3.14 Merck
13.3.15 Eisai Co., Ltd.
Note: Product cover images may vary from those shown
3 of 4
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly
  • Novartis
  • Pfizer Inc.
  • Sanofi S.A.
  • Actelion
  • Baxter International Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Amgen Inc.
  • F.Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Eisai Co. Ltd.
Note: Product cover images may vary from those shown
4 of 4